Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Naltrexone
Drug ID BADD_D01527
Description Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
Indications and Usage Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
Marketing Status approved; investigational; vet_approved
ATC Code N07BB04
DrugBank ID DB00704
KEGG ID D05113
MeSH ID D009271
PubChem ID 5360515
TTD Drug ID D0PG8O
NDC Product Code 16447-0689; 69641-0002; 82105-003; 0406-3940; 65757-300; 0406-4605; 43798-006; 65757-360; 65757-301
UNII 5S6W795CQM
Synonyms Naltrexone | Antaxone | Trexan | EN-1639A | EN 1639A | EN1639A | ReVia | Nemexin | Nalorex | Naltrexone Hydrochloride | Celupan
Chemical Information
Molecular Formula C20H23NO4
CAS Registry Number 16590-41-3
SMILES C1CC1CN2CCC34C5C(=O)CCC3(C2CC6=C4C(=C(C=C6)O)O5)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Thirst14.03.02.007; 08.01.09.021--Not Available
Tinea pedis23.11.03.012; 11.03.08.004--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tooth abscess11.01.04.003; 07.09.01.003--Not Available
Toothache07.09.06.001--
Tremor17.01.06.002--
Ulcer08.03.06.001--Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Weight increased13.15.01.006--
White blood cell count increased13.01.06.013--Not Available
Withdrawal syndrome19.07.06.023; 08.06.02.012--Not Available
Yawning22.12.03.037--Not Available
Energy increased08.01.03.017--Not Available
Seasonal allergy22.04.04.008; 10.01.04.001; 06.04.01.013--Not Available
Muscle strain12.01.07.004; 15.05.07.002--Not Available
Deep vein thrombosis24.01.02.003--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Lymphatic disorder01.09.01.003--Not Available
Perirectal abscess11.01.07.005; 07.19.04.001--Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Alcohol withdrawal syndrome19.07.06.005; 08.06.02.002--Not Available
Nodule08.03.05.002--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene